Genedata Expressionist Extends Support of MAM for Biotherapeutics Characterization

Genedata significantly improves support of Multi-Attribute Methods (MAM), extends quantification functionalities, and provides new reporting capabilities in its leading software platform for the characterization of biopharmaceuticals.

Berlin, Germany

Genedata, a leading provider of advanced software solutions for drug discovery and development, today announced the release of version 10.5 of its market-leading mass spectrometry software platform Genedata Expressionist®. This latest version delivers important new features, in particular support of the application of multi-attribute methods (MAMs) for the characterization of biotherapeutics. Release 10.5 will be demonstrated in September at the Bioanalytical and Formulation Summit in Berlin, Germany and at the CASSS mass spectrometry meeting, the 13th Symposium on the Practical Application of Mass Spectrometry in the Biotechnology Industry, in San Diego, USA.

Genedata Expressionist addresses rapidly evolving needs in major biopharmaceutic

< | >